Treace Medical Concepts, Inc.

Treace Medical Concepts, Inc.

TMCINYSE / NASDAQHealthcareSmall cap

$4.31-$0.04 (-0.9%)

Last close · Data as of Nov 20, 2026

Market cap
$239.4M
P/E
-4.1x
EV / EBITDA
-7.0x
Revenue
$212.7M
Net margin
-27.7%
ROCE
-33.9%

+65.1% over the last year

Treace Medical Concepts, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+5.9%
3M
-3.4%
6M
+52.8%
1Y
+65.1%
5Y
Hidden
  • This period includes a one-day price step on 8 May 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.04 (-0.9%) from $4.35 to $4.31 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TMCI, bought on each weekday since 2021.

News & filings

What Treace Medical Concepts filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 59.0 million US dollars in fiscal 2025.

Strengths (1)

  • The price is 26.9% above its 200-day average, and the 50-day average is above the 200-day.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.

Read moreShow less

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

Sector
Healthcare
Shares outstanding
63.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$239.4M
P/E
-4.1x
P/B
2.7x
EV / EBITDA
-7.0x
EV / Sales
1.4x
P/S
1.1x
52-week high
$5.34
52-week low
$1.20

Profitability

Operating margin
-25.5%
Net margin
-27.7%
EBITDA margin
-20.2%
ROE
-67.6%
ROCE
-33.9%
ROIC
-28.6%
ROA
-31.0%
Asset turnover
1.12

Growth

Revenue
$212.7M
Revenue growth, 1Y
1.6%
Revenue CAGR, 3Y
14.5%
Net profit growth, 1Y
5.8%
Free cash flow
-$29.5M

Solvency

Current ratio
4.31
Debt / Equity
0.82
Debt / Assets
0.38
CFO / Net profit
0.27
Cash / Market cap
4.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$212.7M
Cost of revenue$42.9M
Gross profit$169.8M
Operating expenses$223.9M
Research and development$20.3M
Selling, general and administrative$203.6M
Operating income-$54.1M
Interest and other-$4.9M
Pretax income-$59.0M
Tax and other$0.00
Net income-$59.0M

Revenue and net profit

Revenue grew 1.6% in FY2025; net profit is the dashed line.

Treace Medical Concepts, Inc. revenue and net profit by fiscal year
Treace Medical Concepts, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$141.8M-$42.8M
FY2023$187.1M-$49.5M
FY2024$209.4M-$55.7M
FY2025$212.7M-$59.0M

Cash flows

FY2025: -$16.0M from operations, -$29.5M free after investment (dashed).

Treace Medical Concepts, Inc. operating and free cash flow by fiscal year
Treace Medical Concepts, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$30.6M-$45.5M
FY2023-$34.6M-$46.0M
FY2024-$37.2M-$48.8M
FY2025-$16.0M-$29.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$212.7M+1.6%1Y
EBITDA
-$43.1M
Net profit
-$59.0M
Cash from operations
-$16.0M
Free cash flow
-$29.5M
Revenue CAGR, 3Y
14.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$212.7M-$43.1M-$59.0M-$29.5M-67.6%+1.6%+5.8%

Monthly returns

Month-by-month returns of TMCI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$190.6M
Liabilities$103.3M
Equity$87.3M
Paid-in capital$337.4M
Retained earnings-$249.0M
Treasury stock$1.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TMCI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Treace Medical Concepts, Inc. (this company)1.4x

Not shown (no positive earnings and no EV / Sales): Protara Therapeutics, Inc., Fulcrum Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Treace Medical Concepts, Inc.TMCIthis company$239.4M-4.1x2.7x-67.6%-7.0x
Sight Sciences, Inc.SGHT$250.3M-6.5x3.9x-60.1%-6.1x
Protara Therapeutics, Inc.TARA$247.9M-4.3x1.3x-29.2%-3.1x
Coherus Oncology, Inc.CHRS$242.9M1.4x4.0x275.4%-1.1x
LifeMD, Inc.LFMD$235.5M16.4x10.2x62.0%-135.2x
Arcturus Therapeutics Holdings Inc.ARCT$228.5M-3.5x1.1x-30.7%-0.4x
Spok Holdings, Inc.SPOK$228.3M14.4x1.6x10.8%8.9x
LENZ Therapeutics, Inc.LENZ$225.8M—0.8x-28.9%—
Fulcrum Therapeutics, Inc.FULC$224.6M—0.6x-21.5%—
Peer median—-1.0x1.4x-25.2%-2.1x

Year-to-date ROI

TMCI since 1 January, against earlier years.

Historical volatility

TMCI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Treace Medical Concepts, Inc. operating margin by fiscal year
Treace Medical Concepts, Inc. operating margin by fiscal year
DateOperating margin
FY2022-24.6%
FY2023-27.5%
FY2024-26.6%
FY2025-25.5%
LineFY2025
Cost of revenueCost Of Revenue$42.9M
Gross profitGross Profit$169.8M
Operating expensesOperating Expense$223.9M
Research and developmentResearch And Development$20.3M
Total expensesTotal Expenses$266.8M
Pretax incomePretax Income-$59.0M

Learn while you research

Academy chapters picked for Treace Medical Concepts, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →